Literature DB >> 2553433

Comparison of the behavioral and biochemical effects of the NMDA receptor antagonists, MK-801 and phencyclidine.

M Hiramatsu1, A K Cho, T Nabeshima.   

Abstract

The behavioral and biochemical effects of the noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, MK-801 [+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate) were compared with those of phencyclidine (PCP). In the dose range used in this study, MK-801 (0.125-0.5 mg/kg i.p.) produced ataxia and other behavioral responses which were similar to PCP (5-10 mg/kg i.p.). However, turning and backpedalling induced by MK-801 were not dose-dependent and less intense at the dose producing approximately the same level of ataxia as PCP. Neurochemically, MK-801 (0.5 mg/kg i.p.) increased dopamine turnover in the cortex and striatum, but had no effect on 5-HT systems. It was also 3.4 times less potent in inhibiting 5-HT uptake than PCP. These results suggest that the behavioral responses induced by MK-801 involve primarily the PCP receptor and the dopamine system, and that the differences from PCP reflect a reduced effect on the 5-HT neuronal system.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2553433     DOI: 10.1016/0014-2999(89)90346-4

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  30 in total

1.  Hyperfunction of dopaminergic and serotonergic neuronal systems in mice lacking the NMDA receptor epsilon1 subunit.

Authors:  Y Miyamoto; K Yamada; Y Noda; H Mori; M Mishina; T Nabeshima
Journal:  J Neurosci       Date:  2001-01-15       Impact factor: 6.167

2.  Modulation of MK-801 response by dopaminergic agents in mice.

Authors:  A Verma; S K Kulkarni
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

3.  Enantiomeric propanolamines as selective N-methyl-D-aspartate 2B receptor antagonists.

Authors:  Yesim A Tahirovic; Matthew Geballe; Ewa Gruszecka-Kowalik; Scott J Myers; Polina Lyuboslavsky; Phuong Le; Adam French; Hasan Irier; Woo-Baeg Choi; Keith Easterling; Hongjie Yuan; Lawrence J Wilson; Robert Kotloski; James O McNamara; Raymond Dingledine; Dennis C Liotta; Stephen F Traynelis; James P Snyder
Journal:  J Med Chem       Date:  2008-09-25       Impact factor: 7.446

4.  Developmental vitamin D deficiency alters MK-801-induced behaviours in adult offspring.

Authors:  James P Kesby; Jonathan C O'Loan; Suzanne Alexander; Chao Deng; Xu-Feng Huang; John J McGrath; Darryl W Eyles; Thomas H J Burne
Journal:  Psychopharmacology (Berl)       Date:  2011-09-21       Impact factor: 4.530

5.  Rewarding actions of phencyclidine and related drugs in nucleus accumbens shell and frontal cortex.

Authors:  W A Carlezon; R A Wise
Journal:  J Neurosci       Date:  1996-05-01       Impact factor: 6.167

6.  MK801-induced locomotor activity in preweanling and adolescent male and female rats: role of the dopamine and serotonin systems.

Authors:  Sanders A McDougall; Matthew G Apodaca; Ginny I Park; Angie Teran; Timothy J Baum; Nazaret R Montejano
Journal:  Psychopharmacology (Berl)       Date:  2020-05-22       Impact factor: 4.530

7.  Antidepressant drugs increase the locomotor hyperactivity induced by MK-801 in rats.

Authors:  J Maj; Z Rogóz; G Skuza
Journal:  J Neural Transm Gen Sect       Date:  1991

8.  Phencyclidine block of calcium current in isolated guinea-pig hippocampal neurones.

Authors:  J M Ffrench-Mullen; M A Rogawski
Journal:  J Physiol       Date:  1992-10       Impact factor: 5.182

9.  Role of dopaminergic neuronal system in dizocilpine-induced acetylcholine release in the rat brain.

Authors:  M Hasegawa; K Yamada; T Hasegawa; T Nabeshima
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

10.  Motor actions of eliprodil in the normal and monoamine-depleted mouse: a role in the treatment of Parkinson's disease?

Authors:  S Brooks; S Kaur; B S Starr; M S Starr
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.